Salesforce

Measure Paper - CMS 2025 Measure 135v13 for NextGen Office

« Go Back

Information

 
Application Version
Program/Measure Year
Build Version
Document Summary
DomainCommunity/Population Health 
Measure Name CMS 135v13 Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD)
 Description  Percentage of patients aged 18 years and older with a diagnosis of heart failure (HF) with a current or prior left ventricular ejection fraction (LVEF) < 40% who were prescribed ACE inhibitor or ARB or ARNI therapy either within a 12-month period when seen in the outpatient setting OR at each hospital discharge. 
In the Attachments section of the article, locate the measure paper for NextGen Healthcare Solution.
Attachment 1NextGen Health Quality Measure

 

Attachment 1
Attachment 2
Attachment 3
Attachment 4
Attachment 5
KeywordseCQM CMS135 "heart failure" HF "left ventricular ejection fraction" LVEF LVSD "angiotensin-converting enzyme" "ACE inhibitor" "angiotensin receptor blocker" ARB "angiotensin receptor-neprilysin inhibitor" ARNI MIPS
TitleMeasure Paper - CMS 2025 Measure 135v13 for NextGen Office
URL NameCMS135

Powered by